SynthesisEndocrinology and metabolism (Seoul, Korea)2024
Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review.
Synthesis in Endocrinology and metabolism (Seoul, Korea), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07584447 (Clinical Utility of Preoperative Thyroid GuidePx® Testing), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Utility of Preoperative Thyroid GuidePx® Testing
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Ablative Technologies for Thyroid Nodules: A Health Technology Assessment.Ontario health technology assessment series · 2026Pooled it
- 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2025Guideline
- Patterns of complementary and alternative medicine use and factors influencing its utilization in thyroid cancer: findings from the MASTER study.BMC complementary medicine and therapies · 2026Trial
- BRAF Mutation and Tumor Growth Kinetics during Active Surveillance of Papillary Thyroid Microcarcinoma: A Single-Center Retrospective Study.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer: Protocol of a Multicenter Cluster-Randomized Trial (MAeSTro-SDM).Journal of Korean medical science · 2026Article
- Risk factors associated with lymph node metastasis in cN0 papillary thyroid microcarcinoma.Frontiers in oncology · 2026Article
- The Luo-Dingyuan Thyroid Vascular-Lymphatic Segmentation Classification: A Functional Anatomy-Based Framework to Facilitate Precision Management and Thyroid Function Preservation.Cancer management and research · 2026Article
- Risk factors for lateral neck lymph node metastasis in papillary thyroid ultra micro carcinoma with implications for active surveillance.Scientific reports · 2025Article
- Global research landscape on active surveillance for papillary thyroid microcarcinoma: a bibliometric analysis.Discover oncology · 2025Article
- A national survey of physicians regarding active surveillance for low-risk thyroid cancer in Korea.European thyroid journal · 2025Article
- From screening to follow-up: a review of quality of life and psychological status across the clinical care continuum in patients with differentiated thyroid cancer.Frontiers in psychology · 2025Review
- It Is Time to Understand the Additional Benefits of Active Surveillance for Low-Risk Papillary Thyroid Carcinoma.Endocrinology and metabolism (Seoul, Korea) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgruoundActive surveillance (AS) has been introduced as a management strategy for low-risk papillary thyroid carcinoma (PTC) due to its typically indolent nature. Despite this, the widespread adoption of AS has encountered several challenges. The aim of this systematic review was to evaluate the safety of AS related to disease progression and its benefits compared with immediate surgery (IS).
methodsStudies related to AS in patients with low-risk PTC were searched through the Ovid MEDLINE, Embase, Cochrane Library, and KoreaMed databases. Studies on disease progression, surgical complication, quality of life (QoL), and cost-effectiveness were separately analyzed and narratively synthesized.
resultsIn the evaluation of disease progression, the proportions of cases with tumor growth ≥3 mm and a volume increase >50% were 2.2%-10.8% and 16.0%-25.5%, respectively. Newly detected lymph node metastasis was identified in 0.0%-1.4% of patients. No significant difference was found between IS and delayed surgery in surgical complications, including vocal cord paralysis and postoperative hypoparathyroidism. AS was associated with better QoL than IS. Studies on the cost-effectiveness of AS reported inconsistent data, but AS was more cost-effective when quality-adjusted life years were considered.
conclusionAS is an acceptable management option for patients with low-risk PTC based on the low rate of disease progression and the absence of an increased mortality risk. AS has additional benefits, including improved QoL and greater QoL-based cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.